- Home
- MQT vs NKTR Comparison
MQT vs NKTR Comparison
Compare MQT & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQT
- NKTR
- Stock Information
- Founded
- MQT 1992
- NKTR 1990
- Country
- MQT United States
- NKTR United States
- Employees
- MQT N/A
- NKTR N/A
- Industry
- MQT Investment Bankers/Brokers/Service
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- MQT Finance
- NKTR Health Care
- Exchange
- MQT Nasdaq
- NKTR Nasdaq
- Market Cap
- MQT 210.8M
- NKTR 108.3M
- IPO Year
- MQT N/A
- NKTR 1994
- Fundamental
- Price
- MQT $9.56
- NKTR $24.25
- Analyst Decision
- MQT
- NKTR Strong Buy
- Analyst Count
- MQT 0
- NKTR 6
- Target Price
- MQT N/A
- NKTR $81.67
- AVG Volume (30 Days)
- MQT 52.5K
- NKTR 4.8M
- Earning Date
- MQT 01-01-0001
- NKTR 08-07-2025
- Dividend Yield
- MQT 4.60%
- NKTR N/A
- EPS Growth
- MQT N/A
- NKTR N/A
- EPS
- MQT N/A
- NKTR N/A
- Revenue
- MQT N/A
- NKTR $87,248,000.00
- Revenue This Year
- MQT N/A
- NKTR N/A
- Revenue Next Year
- MQT N/A
- NKTR N/A
- P/E Ratio
- MQT N/A
- NKTR N/A
- Revenue Growth
- MQT N/A
- NKTR N/A
- 52 Week Low
- MQT $8.59
- NKTR $6.48
- 52 Week High
- MQT $10.67
- NKTR $37.38
- Technical
- Relative Strength Index (RSI)
- MQT 45.78
- NKTR 63.40
- Support Level
- MQT $9.56
- NKTR $21.87
- Resistance Level
- MQT $9.58
- NKTR $26.59
- Average True Range (ATR)
- MQT 0.06
- NKTR 4.14
- MACD
- MQT 0.00
- NKTR 0.01
- Stochastic Oscillator
- MQT 36.36
- NKTR 54.77
About MQT Blackrock MuniYield Quality Fund II Inc.
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, Housing, Corporate, and Tobacco.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.